HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Masaaki Ochi Selected Research

Resistin

1/2010A at single nucleotide polymorphism-358 is required for G at -420 to confer the highest plasma resistin in the general Japanese population.
9/2009PPARgamma Pro12Ala Pro/Pro and resistin SNP-420 G/G genotypes are synergistically associated with plasma resistin in the Japanese general population.
7/2008Serum resistin is positively correlated with the accumulation of metabolic syndrome factors in type 2 diabetes.
2/2008Serum resistin is reduced by glucose and meal loading in healthy human subjects.
2/2008Hyperresistinemia is associated with coexistence of hypertension and type 2 diabetes.
11/2007Frequency of the G/G genotype of resistin single nucleotide polymorphism at -420 appears to be increased in younger-onset type 2 diabetes.
6/2007Plasma resistin, associated with single nucleotide polymorphism -420, is correlated with insulin resistance, lower HDL cholesterol, and high-sensitivity C-reactive protein in the Japanese general population.
4/2007Serum resistin is associated with the severity of microangiopathies in type 2 diabetes.
9/2005Resistin SNP-420 determines its monocyte mRNA and serum levels inducing type 2 diabetes.
10/2004The G/G genotype of a resistin single-nucleotide polymorphism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Masaaki Ochi Research Topics

Disease

13Insulin Resistance
01/2010 - 03/2002
5Hypertension (High Blood Pressure)
07/2008 - 09/2003
3Atherosclerosis
07/2008 - 06/2006
3Hyperlipidemias (Hyperlipidemia)
08/2007 - 09/2003
3Type 2 Diabetes Mellitus (MODY)
09/2005 - 10/2004
2Obesity
07/2008 - 09/2003
2Diabetic Angiopathies (Diabetic Angiopathy)
03/2008 - 04/2007
1Diabetic Retinopathy (Retinopathy, Diabetic)
03/2008
1Hypotension (Low Blood Pressure)
06/2007

Drug/Important Bio-Agent (IBA)

12ResistinIBA
01/2010 - 03/2002
2Glucose (Dextrose)FDA LinkGeneric
07/2008 - 02/2008
2Insulin Receptor Substrate ProteinsIBA
07/2008 - 11/2002
2HDL CholesterolIBA
02/2008 - 06/2007
2Insulin (Novolin)FDA Link
11/2002 - 03/2002
1Triglycerides (Triacylglycerol)IBA
07/2008
1Phosphotransferases (Kinase)IBA
07/2008
1Serine (L-Serine)FDA Link
07/2008
1Mitogen-Activated Protein Kinase 8IBA
07/2008
1AdiponectinIBA
03/2008
1CreatinineIBA
03/2008
1Carrier Proteins (Binding Protein)IBA
02/2008
1AdipokinesIBA
02/2008
1LDL CholesterolIBA
08/2007
1C-Reactive ProteinIBA
06/2007
1Apolipoproteins B (ApoB)IBA
06/2006
1LDL glycosylated lipoproteinsIBA
06/2005
1Type 3 Cyclic Nucleotide PhosphodiesterasesIBA
09/2003
1Sterol Esterase (Hormone-Sensitive Lipase)IBA
09/2003